دورية أكاديمية

Pelabresib Plus Ruxolitinib Combination Therapy in JAK Inhibitor-Naïve Patients With Myelofibrosis in the Phase 3 MANIFEST-2 Study: Preliminary Evidence of Bone Marrow Recovery

التفاصيل البيبلوغرافية
العنوان: Pelabresib Plus Ruxolitinib Combination Therapy in JAK Inhibitor-Naïve Patients With Myelofibrosis in the Phase 3 MANIFEST-2 Study: Preliminary Evidence of Bone Marrow Recovery
المؤلفون: Mascarenhas, John, Rampal, Raajit K., Vannucchi, Alessandro M., Gupta, Vikas, Oh, Stephen T., Kuykendall, Andrew T., Mesa, Ruben, Kiladjian, Jean-Jacques, Talpaz, Moshe, Kremyanskaya, Marina, Scandura, Joseph, Kräft, Tabea, Eliane, Jean-Pierre, Chang, Tzuu-Wang, Cui, Jike, Kuffer, Christian, Boxhammer, Rainer, Harrison, Claire
المصدر: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S200-S200
قاعدة البيانات: ScienceDirect
الوصف
تدمد:21522650
DOI:10.1016/S2152-2650(24)00705-5